+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regorafenib approved in Metastatic Colorectal cancer



Regorafenib approved in Metastatic Colorectal cancer



Bulletin du Cancer 100(10): 1027-1029



Regorafenib, oral multi-kinase inhibitor that targets oncogenesis, tumor angiogenesis and maintenance of the tumor microenvironment, obtained its European approval, August 26, 2013 after favorable review of the European Medecines Agency in the following indication: treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy or are not considered candidates for available therapies and, if KRAS wild type, an anti-EGFR therapy. This decision was based on the efficacy and safety results of an international phase III trial. This study showed an improved overall survival, with régorafénib versus placebo (6.4 months vs 4 months; HR = 0.774, IC à 95%, 0.64 à 0.94; p = 0,005 2). Reported grade 3-4 adverse events with regorafenib were hand-foot syndrome (17%), asthenia (10%), diarrhea (7%), hypertension (7%), rash and desquamation (6%).

(PDF emailed within 0-6 h: $19.90)

Accession: 055446598

Download citation: RISBibTeXText

PMID: 24047557

DOI: 10.1684/bdc.2013.1808


Related references

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer 8(1): 22-26, 2019

Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biology and Therapy 16(12): 1710-1719, 2016

Regorafenib for metastatic colorectal cancer. Lancet 381(9877): 1537-1537, 2013

Regorafenib in metastatic colorectal cancer. Expert Review of Anticancer Therapy 14(3): 255-265, 2014

Regorafenib for metastatic colorectal cancer. Lancet 381(9877): 1537-1538, 2013

Regorafenib in metastatic colorectal cancer. Clinical Advances in Hematology and Oncology 10(5): 324-325, 2015

Regorafenib in the treatment of metastatic colorectal cancer. Future Oncology 14(22): 2239-2246, 2018

The role of regorafenib in metastatic colorectal cancer. Lancet. Oncology 16(6): 596-597, 2015

Regorafenib: A Review in Metastatic Colorectal Cancer. Drugs 78(11): 1133-1144, 2018

FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology 26(10): 896-896, 2012

Regorafenib (Stivarga) for metastatic colorectal cancer and GIST. Medical Letter on Drugs and Therapeutics 55(1415): E36-E36, 2013

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. Journal of Clinical Oncology 33(32): 3727-3732, 2016

Regorafenib in patients with metastatic colorectal cancer: a review and an update. Recenti Progressi in Medicina 106(12): 629-633, 2016

Appropriateness of Regorafenib Administration to Patients with Metastatic Colorectal Cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 45(13): 2012-2014, 2019

Treatment of metastatic refractory colorectal cancer following regorafenib failure. Molecular and Clinical Oncology 7(2): 308-312, 2017